Longeveron (NASDAQ:LGVN) Releases Quarterly Earnings Results, Misses Estimates By $0.21 EPS

Longeveron (NASDAQ:LGVN) issued its quarterly earnings results on Thursday. The company reported ($1.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.21), FiscalAI reports. Longeveron had a negative net margin of 1,977.59% and a negative return on equity of 223.19%. The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.80 million.

Longeveron Price Performance

LGVN opened at $2.97 on Friday. The company’s 50 day simple moving average is $3.01 and its two-hundred day simple moving average is $6.45. Longeveron has a 1-year low of $1.31 and a 1-year high of $12.30. The firm has a market capitalization of $9.47 million, a price-to-earnings ratio of -0.30 and a beta of -0.09.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LGVN shares. Weiss Ratings cut Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th. Wall Street Zen upgraded Longeveron from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $80.00.

Longeveron Company Profile

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.